Bionano Genomics (MEX:BNGO) Total Current Liabilities: MXN382.8 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:BNGO Bionano Genomics Inc MEX:BNGO
61 GF Score
Price MXN20.09
GF Value MXN27.08
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Bionano Genomics Total Current Liabilities?

Bionano Genomics MEX:BNGO 61 Total Current Liabilities is MXN382.8 Mil as of Mar. 2026. GuruFocus rates MEX:BNGO with a GF Score™ of 61/100 and a GF Value™ of MXN27.08 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Bionano Genomics's total current liabilities for the quarter that ended in Mar. 2026 was MXN382.8

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Bionano Genomics Total Current Liabilities Related Terms

Bionano Genomics Total Current Liabilities Historical Data

* Premium members only.

The historical data trend for Bionano Genomics's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bionano Genomics Total Current Liabilities Chart

Bionano Genomics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 448.03 699.59 1,697.90 778.84 413.09

Bionano Genomics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 540.26 455.25 421.50 413.09 382.80
MEX:BNGO
61GF Score
Bionano Genomics Inc MEX:BNGO
Total Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bionano Genomics Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Bionano Genomics's Total Current Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=125.176+17.033
+Other Current Liabilities+Current Deferred Liabilities
=253.466+17.412
=413.1

Bionano Genomics's Total Current Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=108.196+199.153
+Other Current Liabilities+Current Deferred Liabilities
=55.144+20.305
=382.8

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

What does a Total Current Liabilities of MXN382.8 Mil mean?
Bionano Genomics (MEX:BNGO) has a Total Current Liabilities of MXN382.8 Mil as of Mar. 2026. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Bionano Genomics and its competitors.
Is Bionano Genomics' Total Current Liabilities too high?
Bionano Genomics' current Total Current Liabilities is MXN382.8 Mil. Overall, Bionano Genomics has a GF Score™ of 61/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bionano Genomics' Total Current Liabilities compare to UEEC and CUPR?
Bionano Genomics' Total Current Liabilities of MXN382.8 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Liabilities for a Medical Devices & Instruments company?
A good Total Current Liabilities depends on the Medical Devices & Instruments industry context. However, Total Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Liabilities mean?
A high Total Current Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Bionano Genomics and its competitors. Bionano Genomics's current Total Current Liabilities is MXN382.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bionano Genomics stock overvalued right now?
Based on GuruFocus' analysis, Bionano Genomics (MEX:BNGO) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN27.08, compared to a current price of MXN20.09 — trading 25.8% below its estimated fair value. The current Total Current Liabilities is MXN382.8 Mil. Bionano Genomics' overall GF Score™ is 61/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Liabilities calculated?
Total Current Liabilities is calculated from a company's financial statements. For Bionano Genomics (MEX:BNGO), the current Total Current Liabilities is MXN382.8 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bionano Genomics (MEX:BNGO) Overvalued in 2026?

Based on GuruFocus' analysis, Bionano Genomics stock appears to be undervalued. The current stock price of MXN20.09 is trading 25.8% below its estimated GF Value™ of MXN27.08. GuruFocus considers Bionano Genomics to be Modestly Undervalued.

Key valuation signals for MEX:BNGO:

  • Total Current Liabilities: MXN382.8 Mil
  • GF Value™: MXN27.08 vs. price of MXN20.09 (25.8% below fair value)
  • GF Score™: 61/100 with 3 warning signs

No single metric tells the full story. See the MEX:BNGO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bionano Genomics Business Description

Other Exchanges BNGO:USA
Address 9540 Towne Centre Drive, Suite 100, San Diego, CA, USA, 92121
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in the Americas, EMEA, and Asia Pacific, of which the EMEA region generates the majority of its revenue. It generates product revenue from sales of its OGM and Ionic Purification systems and consumables, which include its instruments and their VIA software.
61GF Score

Get the complete analysis for MEX:BNGO

Total Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN20.09
Price
MXN27.08
GF Value